Avid Bioservices, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Apr 30, 2024	FY2023 12 months to Apr 30, 2023	FY2022 12 months to Apr 30, 2022	FY2021 12 months to Apr 30, 2021	FY2020 12 months to Apr 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Stock-based compensation
Amortization of debt issuance costs
Deferred income taxes
Loss on extinguishment of convertible senior notes due 2026
Loss on disposal and/or impairment of property and equipment
Gain on sale of research and development assets
Changes in operating assets and liabilities:
Accounts receivable, net
Contract assets
Inventory
Prepaid expenses and other assets
Accounts payable
Accrued compensation and benefits
Contract liabilities
Other accrued expenses and liabilities
Assets and liabilities of discontinued operations
Net cash provided by (used in) operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
Proceeds from sale of property and equipment
Proceeds from sale of research and development assets
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible senior notes due 2029, net
Purchases of capped calls related to convertible senior notes
Repayment of note payable
Dividends paid on preferred stock
Redemption of preferred stock
Impact of preferred stock redemption
Repurchase and/or payoff of convertible senior notes due 2026
Proceeds from unwinding of capped calls related to repurchase of convertible senior notes due 2026
Proceeds from issuance of common stock under equity compensation plans
Proceeds from note payable
Proceeds from issuance of common stock, net of issuance costs
Proceeds from exercise of stock options
Proceeds from finance lease
Principal payments on finance leases
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for income taxes

Supplemental disclosures of non-cash investing and financing activities:
Unpaid purchases of property and equipment
Right-of-use assets obtained upon operating lease modification, net
Property and equipment obtained in exchange for finance lease obligation
Decapitalization of right-of-use assets upon lease termination and/or modification
Property and equipment acquired under finance lease
Receivable related to the sale of research and development assets
Unpaid issuance costs associated with convertible senior notes due 2029

Comments